TacticScaleWhat BioLife Solutions Does & How It Makes Money (BLFS)
Updated October 2026 · reflects BioLife Solutions's latest reported financials
Maker of cell storage, freezing, and shipping products for cell therapies. The company earns revenue by selling biopreservation media, cell-processing consumables, and equipment such as thawing devices and smart shipping containers to cell and gene therapy developers and manufacturers.
How BioLife Solutions makes money
The company earns revenue by selling biopreservation media, cell-processing consumables, and equipment such as thawing devices and smart shipping containers to cell and gene therapy developers and manufacturers. It sells directly and through third-party distributors.
What BioLife Solutions does
BioLife Solutions, based in Bothell, Washington and incorporated in 1987, supplies bioproduction tools to the cell and gene therapy (CGT) industry. Its core products are proprietary biopreservation media, CryoStor and HypoThermosol FRS, which are formulated to reduce the cell damage and death that can appear after preservation. Customers use these products in basic and applied research and in commercial manufacturing of biologic-based therapies. The company also sells products for other steps in the workflow: human platelet lysates for growing cells, CellSeal closed vials, CryoCase rigid containers, automated cell processing machines, ThawSTAR automated thawing devices, and evo cloud-connected passive shipping containers for temperature-sensitive biologics. It sells in the US, Europe, the Middle East, Africa, and other international markets, both directly and through distributors. How well it does depends largely on growth in cell and gene therapy development and commercialization.
Products & services
- CryoStor Freeze Media
- HypoThermosol FRS
- CellSeal closed system vials
- CryoCase containers
- ThawSTAR automated thawing devices
- evo cloud-connected shipping containers
What is BioLife Solutions worth?
On an owner-earnings DCF, BioLife Solutions's most-likely value is about $13 versus a recent price near $39 (67% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$2) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ Capital-intensive — this business reinvests heavily, so free cash flow runs well below its earnings. Fair value here is built on free cash flow, which understates owner earnings for reinvestment-heavy companies — read it as conservative.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Bio-Techne (TECH) · Bio-Thera Solutions (688177.SS) · Qingdao Haier Biomedical (688139.SS) · Sino Biological,Inc (301047.SZ)